B+
Overall grade
B
Financial quality
The sleeper story is MAGNITUDE's 57% patient expansion masquerading as confidence but actually reveals event rate concerns - when you need that many more patients for 'statistical power in the stabilizer stratum,' it means your TTR knockdown isn't translating to clinical events as cleanly as hoped. The obvious headline is record HAE enrollment, but the real story is binary response creating unblinding risk they're dodging. The binding constraint is proving clinical benefit over tafamidis, not enrollment speed or manufacturing capacity. Most revealing quote: 'We want to have a highly statistically significant finding...for patients on stabilizer' - translation: the current data isn't compelling enough. My view changes if they provide specific event rate assumptions or interim analysis criteria showing confidence in current effect size.
The 30-second version
- MAGNITUDE cardiomyopathy expansion to 1,200 patients signals deeper event rate concerns than market realizes
- HAE enrollment completed in record 4 months screaming unmet need, but redosing elephant in room
- David Lebwohl retirement announcement buried but signals succession planning around pivotal readouts
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Cash & Equivalents | $707.1M (vs $861.7M Q4 2024) | $630.5M (vs $707.1M Q1 2025) |
| Collaboration Revenue | $16.6M (vs $28.9M Q1 2024) | $14.2M (vs $6.9M Q2 2024) |
| R&D Expenses | $108.4M (vs $111.8M Q1 2024) | $97.0M (vs $114.2M Q2 2024) |
| G&A Expenses | $29.0M (vs $31.1M Q1 2024) | $27.2M (vs $31.8M Q2 2024) |
| Stock-Based Comp (Total) | $21.8M ($12.6M R&D + $9.2M G&A) | $22.1M ($14.1M R&D + $8.0M G&A) |
| MAGNITUDE Enrollment Target | More than 550 patients by year-end | At least 650 patients by year-end |
| MAGNITUDE Total Study Size | 765 patients planned | 1,200 patients (subject to health authority review) |
| HAE Phase 3 Enrollment | Dosing first patient Q1, complete by Q3 | Recruitment ended, randomization complete Q3 |
Accountability tracked
8 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →